AU2003284231A1 - Treatment for reactive arthritis or bursitis - Google Patents

Treatment for reactive arthritis or bursitis Download PDF

Info

Publication number
AU2003284231A1
AU2003284231A1 AU2003284231A AU2003284231A AU2003284231A1 AU 2003284231 A1 AU2003284231 A1 AU 2003284231A1 AU 2003284231 A AU2003284231 A AU 2003284231A AU 2003284231 A AU2003284231 A AU 2003284231A AU 2003284231 A1 AU2003284231 A1 AU 2003284231A1
Authority
AU
Australia
Prior art keywords
dosage unit
dosage
pharmaceutical formulation
metronidazole
bursitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003284231A
Other languages
English (en)
Inventor
Ernest L. Bonner Jr.
Robert Hines
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ficaar Inc
Original Assignee
Ficaar Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ficaar Inc filed Critical Ficaar Inc
Publication of AU2003284231A1 publication Critical patent/AU2003284231A1/en
Assigned to FICAAR, INC. reassignment FICAAR, INC. Request for Assignment Assignors: Bonner, Jr., Ernest, HINES, ROBERT
Assigned to HINES, ROBERT, Bonner Jr., Earnest reassignment HINES, ROBERT Amend patent request/document other than specification (104) Assignors: Earnest Bonner Jr., Earnest L. Bonner, ROBERT HINES
Priority to AU2009238327A priority Critical patent/AU2009238327A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2003284231A 2002-10-15 2003-10-14 Treatment for reactive arthritis or bursitis Abandoned AU2003284231A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2009238327A AU2009238327A1 (en) 2002-10-15 2009-11-18 Treatment for reactive arthritis or bursitis

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/271,117 2002-10-15
US10/271,117 US6765000B2 (en) 1999-03-17 2002-10-15 Treatment for reactive arthritis or bursitis
PCT/US2003/032653 WO2004034987A2 (en) 2002-10-15 2003-10-14 Treatment for reactive arthritis or bursitis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2009238327A Division AU2009238327A1 (en) 2002-10-15 2009-11-18 Treatment for reactive arthritis or bursitis

Publications (1)

Publication Number Publication Date
AU2003284231A1 true AU2003284231A1 (en) 2004-05-04

Family

ID=32106409

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2003284231A Abandoned AU2003284231A1 (en) 2002-10-15 2003-10-14 Treatment for reactive arthritis or bursitis
AU2009238327A Abandoned AU2009238327A1 (en) 2002-10-15 2009-11-18 Treatment for reactive arthritis or bursitis

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2009238327A Abandoned AU2009238327A1 (en) 2002-10-15 2009-11-18 Treatment for reactive arthritis or bursitis

Country Status (10)

Country Link
US (3) US6765000B2 (enExample)
EP (1) EP1558266A4 (enExample)
JP (1) JP2006503095A (enExample)
KR (1) KR20050083762A (enExample)
CN (1) CN100584335C (enExample)
AU (2) AU2003284231A1 (enExample)
CA (1) CA2502397A1 (enExample)
CH (1) CH696629A5 (enExample)
MX (1) MXPA05003930A (enExample)
WO (1) WO2004034987A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7691831B2 (en) * 1999-03-17 2010-04-06 Ernest L. Bonner, Jr. Pharmaceutical combination and method for treatment of reactive arthritis or bursitis
US20050137181A1 (en) * 1999-03-17 2005-06-23 Bonner Ernest L. Method for treatment of reactive arthritis or bursitis
US7884090B2 (en) * 1999-03-17 2011-02-08 Ernest L. Bonner, Jr. Compositions and methods for the treatment of arthritis
US6765000B2 (en) * 1999-03-17 2004-07-20 Bonner Jr Ernest L Treatment for reactive arthritis or bursitis
CN1293883C (zh) * 2004-05-21 2007-01-10 邹宏 一种美容修护液及其制备方法
US7312343B2 (en) * 2004-06-02 2007-12-25 Hoffmann-La Roche Inc. Synthesis of α-amino-β-alkoxy-carboxylic acid esters
CN101076342A (zh) * 2004-12-17 2007-11-21 维纳斯药业有限公司 用于对治疗感染提供总解决方案的抗生素组合
WO2006096555A1 (en) * 2005-03-04 2006-09-14 Women And Infants Hospital Of Ri, Inc. Compositions and methods for cancer treatment
KR20090122994A (ko) * 2007-03-23 2009-12-01 몰레큘러 리서치 센터, 인크. 테트라사이클린류를 함유하는 항염증성 조성물 및 이의 치료 용도
US9675727B2 (en) * 2007-04-10 2017-06-13 Mediwise Pty Ltd. Method and device for treating bursitis
EP2018864A1 (en) * 2007-07-23 2009-01-28 Biomet Deutschland GmbH Pharmaceutical composition, substrate comprising a pharmaceutical composition, and use of a pharmaceutical composition
EA201700052A1 (ru) * 2014-08-18 2017-06-30 Фабризио Де Силвестри Применение в одной пилюле, таблетке, капсуле миноциклина, ациклогуанозина, аторвастатина и витамина d для лечения ревматоидного артрита
KR102806503B1 (ko) * 2021-07-29 2025-05-16 가톨릭대학교 산학협력단 렘데시비르와 면역조절제 병용투여법을 통한 자가면역류마티스 질환 치료용 조성물

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2946801A (en) * 1957-06-05 1960-07-26 Standard Oil Co Production of pyridine carboxylic acids
US3148212A (en) * 1961-12-22 1964-09-08 American Cyanamid Co Reductive alkylation process
USRE26253E (en) * 1963-05-17 1967-08-15 And z-alkylamino-g-deoxytetracycline
US4177796A (en) * 1977-08-22 1979-12-11 Franco Vila Jose J Magnetic thermal vibrational device for the treatment of arthritis and the like
US4521411A (en) * 1983-11-04 1985-06-04 Theodora Koloff Analgesic composition
US5728680A (en) * 1987-12-30 1998-03-17 Cytoven J.V. Methods for normalizing numbers of lymphocytes
US5262173A (en) * 1992-03-02 1993-11-16 American Cyanamid Company Pulsatile once-a-day delivery systems for minocycline
US5523297A (en) * 1993-03-02 1996-06-04 The Research Foundation Of State University Of New York Inhibition of excessive phospholipase A2 activity and/or production by non-antimicrobial tetracyclines
WO1994023593A1 (en) * 1993-04-16 1994-10-27 Mccormick & Company, Inc. Encapsulation compositions
GB9425487D0 (en) * 1994-12-16 1995-02-15 Res Inst Osteoarthritis treatment
JPH09136842A (ja) * 1995-11-14 1997-05-27 Shigemasa Sawada 抗慢性関節リウマチ剤
US6093414A (en) * 1997-08-11 2000-07-25 Christopher C. Capelli Silver-based antimicrobial compositions
US5972389A (en) * 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US5952367A (en) * 1997-04-25 1999-09-14 Pak; Kyoungsik Method of treating pain cause by bursitis tendinitis arthritis
US6416779B1 (en) * 1997-06-11 2002-07-09 Umd, Inc. Device and method for intravaginal or transvaginal treatment of fungal, bacterial, viral or parasitic infections
US7303768B2 (en) * 1998-07-24 2007-12-04 Seo Hong Yoo Preparation of aqueous clear solution dosage forms with bile acids
US6326364B1 (en) * 1999-02-08 2001-12-04 Cedars-Sinai Medical Center Use of 5-aminosalicylates as antimicrobial agents
US20050137181A1 (en) * 1999-03-17 2005-06-23 Bonner Ernest L. Method for treatment of reactive arthritis or bursitis
US6765000B2 (en) * 1999-03-17 2004-07-20 Bonner Jr Ernest L Treatment for reactive arthritis or bursitis
US6087382A (en) * 1999-03-17 2000-07-11 Bonner, Jr.; Ernest L. Method for treatment of reactive arthritis or bursitis
US7884090B2 (en) * 1999-03-17 2011-02-08 Ernest L. Bonner, Jr. Compositions and methods for the treatment of arthritis
US6197776B1 (en) * 1999-03-17 2001-03-06 Ernest L. Bonner, Jr. Method for treatment of reactive arthritis or bursitis
WO2002037395A2 (en) * 2000-10-30 2002-05-10 Tririga, Inc. Item specification object management system
EP1359921A4 (en) * 2001-01-19 2006-09-06 Newbiotics Inc METHODS RELATING TO THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES
US20040024624A1 (en) * 2002-07-31 2004-02-05 Ciscon Lawrence A. Method and system for leveraging functional knowledge using a requirement and space planning tool in an engineering project

Also Published As

Publication number Publication date
CA2502397A1 (en) 2004-04-29
EP1558266A2 (en) 2005-08-03
CH696629A5 (de) 2007-08-31
US7053073B2 (en) 2006-05-30
US6765000B2 (en) 2004-07-20
WO2004034987A2 (en) 2004-04-29
JP2006503095A (ja) 2006-01-26
US20050176690A1 (en) 2005-08-11
CN1729006A (zh) 2006-02-01
AU2009238327A1 (en) 2009-12-10
US20050059640A1 (en) 2005-03-17
EP1558266A4 (en) 2007-12-26
US20030055022A1 (en) 2003-03-20
WO2004034987A3 (en) 2004-07-15
CN100584335C (zh) 2010-01-27
KR20050083762A (ko) 2005-08-26
MXPA05003930A (es) 2005-06-17

Similar Documents

Publication Publication Date Title
AU2009238327A1 (en) Treatment for reactive arthritis or bursitis
US6465473B1 (en) Method for treatment of reactive arthritis or bursitis
US6197776B1 (en) Method for treatment of reactive arthritis or bursitis
Raborn et al. Oral acyclovir and herpes labialis: a randomized, double-blind, placebo-controlled study
AU2001280519A1 (en) Method for treatment of reactive arthritis or bursitis
AU768307B2 (en) Compositions comprising methotrexate and pentostatin for treating rheumatoid arthritis
US5883095A (en) Formulations and methods to treat and prevent equine protozoal myeloencephalitis
CN114980876A (zh) 用艾拉菲诺治疗原发性胆汁性胆管炎
US20050137181A1 (en) Method for treatment of reactive arthritis or bursitis
US7691831B2 (en) Pharmaceutical combination and method for treatment of reactive arthritis or bursitis
Meyboom et al. Achilles tendinitis induced by pefloxacin and other fluoroquinolone derivatives
WO1998043644A1 (en) Formulations and methods to treat and prevent equine protozoal myeloencephalitis
CN113825512A (zh) 皮肤红斑狼疮的治疗
WO2023012244A1 (en) Combination therapy
Arie et al. Crystal-associated rheumatic disease: Current management considerations
WO2025167710A1 (zh) 三稠环化合物在制备预防和/或治疗炎性疾病药物中的应用
Powell, SJ & MacLeod Ambilhar, a nitrothiazole derivative, in urinary tract bilharzia
TABLETS SILENCE FEAR. SILENCE INFECIlON.
KR20060078344A (ko) 데커신 및/또는 데커시놀 안젤레이트, 또는 데커신및/또는 데커시놀 안젤레이트를 유효성분으로 하는당귀추출물을 포함하는 헤르페스 감염 치료제 조성물

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted